EUROPEAN MEDICINES AGENCY APPROVED APIXABAN USE IN CARDIOVERSION

EUROPEAN MEDICINES AGENCY APPROVED APIXABAN USE IN CARDIOVERSION

European Medicines Agency approved apixaban use in cardioversion.

Bibliographic Details
Format:	Article
Language:	English
Published:	Столичная издательская компания 2015-09-01
Series:	Рациональная фармакотерапия в кардиологии
Online Access:	https://www.rpcardio.online/jour/article/view/268

Similar Items

EUROPEAN MEDICINES AGENCY APPROVED APIXABAN USE IN CARDIOVERSION
Published: (2015-09-01)

EUROPEAN MEDICINES AGENCY APPROVED APIXABAN USE IN CARDIOVERSION
Published: (2015-09-01)

The incidence of left atrial appendage thrombi on transesophageal echocardiography after pretreatment with apixaban for cardioversion in the real-world practice.
by: Jongmin Hwang, et al.
Published: (2018-01-01)

Biomarker and Companion Diagnostics—A Review of Medicinal Products Approved by the European Medicines Agency
by: Laura Patricia Orellana García, et al.
Published: (2021-11-01)

Extension of the European Medicines Agency (EMA) approval of trifluridine/tipiracil for gastric cancer
by: Maria Alsina, et al.
Published: (2019-09-01)

Cardioversión farmacológica
by: Carlos Arturo Restrepo-Jaramillo
Published: (2016-12-01)

Electrical cardioversion.
by: Sucu Murat, et al.
Published: (2009-01-01)

Apixaban
by: Gianluca Airoldi, et al.
Published: (2013-03-01)

The European Medicines Agency and Family Doctors
by: Mary McCarthy
Published: (2018-08-01)

Preparation of Apixaban Solid Dispersion for the Enhancement of Apixaban Solubility and Permeability
by: Juseung Lee, et al.
Published: (2023-03-01)

Availability and Affordability of Drugs With a Conditional Approval by the European Medicines Agency; Comparison of Korea With Other Countries and the Implications
by: Hye-Young Kwon, et al.
Published: (2018-09-01)

Time to reimbursement and negotiation condition in Italy for drugs approved by the European Medicines Agency during the period 2014-2019
by: Mariangela Prada, et al.
Published: (2020-12-01)

Differentiating Agency Independence: Perceptions from Inside the European Medicines Agency
by: Levan Makhashvili, et al.
Published: (2013-01-01)

Differentiating Agency Independence: Perceptions from Inside the European Medicines Agency
by: Levan Makhashvili, et al.
Published: (2013-02-01)

Physician Involvement in the Activities of the European Medicines Agency
by: Ivana Silva
Published: (2017-11-01)

Cardioversion in Infantile Atrial Flutter
by: Andaleeb Ara, et al.
Published: (2022-11-01)

Pharmacokinetics and Pharmacogenetics of Apixaban
by: A. V. Savinova, et al.
Published: (2020-11-01)

The use of Apixaban for the treatment of an LV thrombus
by: Sadie Bennett, et al.
Published: (2018-09-01)

The European Medicines Agency Approved the New Antibacterial Drugs – Response to the 2017 Who Report on the Global Problem of Multi-Drug Resistance
by: Krajewska Joanna, et al.
Published: (2021-12-01)

THE EUROPEAN MEDICINES AGENCY APPROVED THE NEW ANTIBACTERIAL DRUGS – RESPONSE TO THE 2017 WHO REPORT ON THE GLOBAL PROBLEM OF MULTI-DRUG RESISTANCE
by: Joanna Krajewska, et al.
Published: (2021-12-01)

Comparison of efficacy of pharmacological cardioversion with antazoline and propafenone versus electrical cardioversion in atrial fibrillation during cryoablation
by: Konrad Klocek, et al.
Published: (2024-03-01)

How to Optimize Cardioversion of Atrial Fibrillation
by: K. E. Juhani Airaksinen
Published: (2022-06-01)

ECG changes following cardioversion and defibrillation
by: Swiss Medical Weekly
Published: (2007-10-01)

Rivaroxaban in atrial fibrillation cardioversion: an update
by: Lavalle C, et al.
Published: (2019-05-01)

Cardioversion: What to choose? Etomidate or propofol
by: Pushkar M Desai, et al.
Published: (2015-01-01)

Cardioversión eléctrica en fibrilación auricular
by: Alejandro Orjuela Guerrero
Published: (2016-12-01)

Impact of electric cardioversion on platelet activation.
by: Harald Haidl, et al.
Published: (2021-01-01)

Direct oral anticoagulants for electrical cardioversion
by: A. N. Volovchenko, et al.
Published: (2021-07-01)

Quick reference guide to apixaban
by: Hurst, K, et al.
Published: (2017)

Quick reference guide to apixaban
by: Hurst KV, et al.
Published: (2017-07-01)

Apixaban-Induced Skin Purpura
by: Miryam Moreta Rodríguez, et al.
Published: (2021-09-01)

The Iterative Development of Medicines Through the European Medicine Agency's Adaptive Pathway Approach
by: Giuseppe Nicotera, et al.
Published: (2019-06-01)

Overview of the European Medicines Agency's Experience With Biowaivers in Centralized Applications
by: Ines Lenić, et al.
Published: (2019-09-01)

The use of validated and nonvalidated surrogate endpoints in two European Medicines Agency expedited approval pathways: A cross-sectional study of products authorised 2011-2018.
by: Catherine Schuster Bruce, et al.
Published: (2019-09-01)

Unexpected excessive apixaban exposure: case report of a patient with polymorphisms of multiple apixaban elimination pathways
by: Andrea Huppertz, et al.
Published: (2019-08-01)

Associations between uncertainties identified by the European Medicines Agency and national decision making on reimbursement by HTA agencies
by: Lourens T. Bloem, et al.
Published: (2021-07-01)

Stratified medicine in practice: review of predictive biomarkers in European Medicines Agency (EMA) indications
by: Malottki Kinga, et al.
Published: (2011-12-01)

Regulatory requirements of the European Medicines Agency for evaluation of bioequivalence of modified-release medicinal products
by: D. P. Romodanovsky, et al.
Published: (2019-03-01)

PAROXYSMAL ATRIAL FIBRILLATION: CHOICE OF CARDIOVERSION THERAPY
by: B. A. Tatarskii
Published: (2015-12-01)

PAROXYSMAL ATRIAL FIBRILLATION: CHOICE OF CARDIOVERSION THERAPY
by: B. A. Tatarskii
Published: (2015-12-01)